Pulse Biosciences (NASDAQ:PLSE) Raised to “Sell” at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by equities researchers at StockNews.com to a “sell” rating in a report issued on Wednesday.

Pulse Biosciences Price Performance

PLSE opened at $20.37 on Wednesday. The business has a fifty day moving average price of $17.20 and a 200 day moving average price of $15.63. Pulse Biosciences has a 12 month low of $6.59 and a 12 month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period last year, the business earned ($0.19) earnings per share.

Institutional Trading of Pulse Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rhumbline Advisers raised its position in shares of Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after acquiring an additional 1,608 shares in the last quarter. Quest Partners LLC purchased a new position in Pulse Biosciences in the second quarter valued at approximately $91,000. Bank of New York Mellon Corp raised its holdings in Pulse Biosciences by 23.4% during the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of Pulse Biosciences during the 1st quarter worth approximately $88,000. Finally, Creative Planning boosted its holdings in shares of Pulse Biosciences by 113.9% in the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after buying an additional 11,667 shares in the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.